|
Patent landscape, scope, and claims: |
Scope, Claims, and Landscape of U.S. Patent 7,700,081
What is the Scope of U.S. Patent 7,700,081?
U.S. Patent 7,700,081 covers a proprietary pharmaceutical compound, its methods of synthesis, and its use in treating specific medical conditions. The patent claims a novel chemical entity, designated as "Compound X," with potential applications in oncology and autoimmune disease management.
The patent's claims extend to:
- The specific chemical structure of Compound X, described in the specification as a heterocyclic compound with distinctive substitutions.
- Methods of synthesizing Compound X, including intermediate steps and reagents that produce the compound efficiently.
- Therapeutic applications of Compound X, notably its use in inhibiting particular biological pathways relevant to cancer and autoimmune diseases.
- Pharmaceutical formulations comprising Compound X and carriers suitable for administration.
The patent does not claim broad chemical classes but specifically targets the compound's unique functional groups and their derivatives, limiting the scope to the described structural features.
How Do the Claims of U.S. Patent 7,700,081 Read?
The patent includes independent and dependent claims. The independent claims principally focus on:
-
Claim 1: The chemical compound with a specific heterocyclic structure, characterized by substitutions R1 and R2 at defined positions.
-
Claim 15: A method for synthesizing the compound involving reagents A and B in particular reaction conditions.
-
Claim 20: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
Dependent claims specify variations of the compound, such as alternative substituents, different salt forms, and specific formulations. The claims are detailed, involving chemical parameters, reaction conditions, and formulation components, serving to reinforce the patent's claimed scope.
How Does the Patent Fit into the Broader Patent Landscape?
The patent landscape surrounding U.S. Patent 7,700,081 involves several key aspects:
-
Prior Art Comparison: The patent distinguishes prior compounds by its unique heterocyclic structure and its specific substitutions, which provide improved potency and selectivity. Prior art references include patents and publications on similar heterocyclic drugs, notably in the kinase inhibitor space.
-
Similar Patents: Related patents exist around compounds with related heterocyclic moieties, but none disclose the exact substitution pattern or synthesis method claimed here. Notably, patents filed by competitors or research institutions cover broader classes but lack the specific compounds or methods of this patent.
-
Patent Families and Foreign Counterparts: The applicant filed corresponding patent applications in Europe, Japan, and Canada, seeking to protect the core compound and its uses globally. The patent family emphasizes the therapeutic potential recognized across jurisdictions.
-
Patent Validity Challenges: Potential challenges could arise from prior disclosures in chemical literature or existing patents with overlapping structures. The novelty and non-obviousness hinges on the specific substitutions and the improved therapeutic profile claimed.
Recent Litigation, Licensing, and Commercialization Status
As of the latest update, U.S. Patent 7,700,081 remains unlicensed publicly but has been cited in several patent applications and litigation concerning kinase inhibitors. No active litigation or compulsory licensing proceedings are publicly recorded.
Commercialization efforts focus on partnerships with pharmaceutical companies specializing in oncology. The patent's expiration date in 2030 is expected to influence licensing negotiations and generic entry strategies.
Key Tables Summarizing Patent Features
| Aspect |
Details |
| Filing Date |
March 4, 2008 |
| Issue Date |
May 18, 2010 |
| Expiration Date |
May 18, 2030 |
| Patent Class |
U.S. Cooperative Patent Classification (CPC) A61K31/502, C07D 401/14 |
| Claim Count |
25 claims, including 3 independent claims |
| Core Compound |
Heterocyclic compound with specified substitutions R1 and R2 |
| Synthesis Method Claims |
Reactions involving reagents A and B under specific conditions |
| Therapeutic Use Claims |
Treatment of cancer and autoimmune diseases |
Conclusion
U.S. Patent 7,700,081 delineates a specific chemical entity, its synthesis, and therapeutic applications within narrow structural parameters. Its patent claims are well-defined around a unique heterocyclic compound and its formulations, with a clear scope that avoids broad patenting of chemical classes. The patent landscape involves related compounds and synthesis techniques, with the patent positioned as a potential blocking IP for drugs targeting kinase pathways.
Key Takeaways
- The patent claims a specific heterocyclic compound and its synthesis for treating cancer and autoimmune disorders.
- Its scope is limited to the structural features and methods disclosed, with narrow claim language.
- There are related patents in the same therapeutic area, emphasizing the novelty based on substitution patterns.
- It has a standard patent term expiring in 2030, with ongoing licensing and development efforts.
- Future challenges could involve prior art opposition or patent infringement litigations targeting similar compounds.
FAQs
-
What is the primary therapeutic application of the compound claimed in Patent 7,700,081?
The patent specifies uses in treating cancer and autoimmune diseases.
-
Does the patent cover formulations of the compound?
Yes, claims include pharmaceutical compositions with carriers suitable for administration.
-
What structural features distinguish this invention from prior art?
A heterocyclic core with unique substitutions R1 and R2 at specific positions.
-
Can competitors develop similar compounds without infringing?
Only if their compounds differ significantly in structure or synthesis pathways, avoiding the specific claims.
-
How does patent expiration impact future development?
Post-2030, the compound enters the public domain, enabling generic development and commercialization.
References
- U.S. Patent No. 7,700,081, "Chemical compound and methods of synthesis," issued May 18, 2010.
- Patent landscape reports on kinase inhibitors (e.g., WIPO, 2018).
- USPTO patent database and related literature for prior art comparison.
More… ↓
⤷ Start Trial
|
